Abstract
Introduction
The effect of N-acetylcysteine (NAC) treatment for patients with chronic bronchitis (CB) is controversial. To better understand the role of NAC in CB treatment, we performed a meta-analysis to provide a more accurate estimation of the importance of NAC treatment.
Methods
PubMed, Embase, and CNKI were systematically searched. The pooled relative risk (RR) and 95% confidence intervals (CI) were calculated using either fixed-effect model or random-effect model based on heterogeneity examination. Statistical analyses were performed using the STATA 12.0 and RevMan 5.2.
Results
A total of 11 publications with 775 patients who were taking NAC and 789 controls who were taking placebo were judged eligible regarding inclusion criteria. The pooled analysis demonstrated significant evidence that NAC reduced the frequency of CB exacerbations (RR = 0.81, 95% CI 0.69–0.93, P = 0.004). Patients treated with NAC had significant symptom improvement compared with controls (RR = 1.68, 95% CI 1.13–2.52, P = 0.01). NAC did not significantly increase the risk of adverse effects compared with placebo (RR 0.86, 95% CI 0.67–1.09, P = 0.22). Subgroup analysis was carried out to assess the stability of results. No publication bias was detected during analyses.
Conclusion
There is a role for NAC treatment in the management of CB by reducing symptoms and exacerbations compared with placebo, without increasing the risk of adverse effects. A regular treatment of low dosage (< 1200 mg per day) and a duration of at least 3 months seems to be effective.
Similar content being viewed by others
References
American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:S77–121.
Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):345–65.
Stavem K, Sandvik L, Erikssen J. Can Global Initiative for Chronic Obstructive Lung Disease stage 0 provide prognostic information on long-term mortality in men? Chest. 2006;130(2):318–25.
Xinzhi W. Chronic obstructive pulmonary disease and pulmonary heart disease (Chinese). Beijing: Beijing Press; 1999.
Regan EA, Lynch DA, Curran-Everett D, et al. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern Med. 2015;175(9):1539–49.
Huchon GJ, Vergnenegre A, Neukirch F, Brami G, Roche N, Preux PM. Chronic bronchitis among French adults: high prevalence and underdiagnosis. Eur Respir J. 2002;20(4):806–12.
Donaldson G, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–52.
Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000;16(2):253–62.
Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. QJM. 1995;88(1):61–8.
Medici TC, Radielovic P. Effects of drugs on mucus glycoproteins and water in bronchial secretion. J Int Med Res. 1979;7(5):434–42.
Rahman I, Skwarska E, MacNee W. Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease. Thorax. 1997;52(6):565–8.
Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2(3):187–94.
Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). A consensus statement of the European Respiratory Society (ERS). Eur Respir J. 1995;8(8):1398-420.
Thoracic Society of Australia and New Zealand. Guidelines for the management of chronic obstructive pulmonary disease. Mod Med Aus. 1995;38:132–6.
Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24(137):451–61.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
Deeks JJ, Higgins JPT, Altman DG. Analysing and presenting results. In: Cochrane Reviewers’ Handbook 4.2.2. Updated March 2004. Chichester: Wiley; 2004. p. 68–139.
Fleiss JL. Analysis of data from multiclinic trials. Control Clin Trials. 1986;7(4):267–75.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
Deeks JJ, Higgins JPT, Ad G. Chapter 9: analysing data and undertaking meta-analysis. In: Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions version 501. Oxford: The Cochrane Collaboration; 2008.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
Jackson IM, Barnes J, Cooksey P. Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: a double-blind placebo controlled study. J Int Med Res. 1984;12(3):198–206.
British Thoracic Society Research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax. 1985;40(11):832–5.
Meister R. Langzeittherapie mit Acetylcystein Retard Tabletten bei Patienten mit chronischer Bronchitis. Eine doppelblinde-placebokontrollierte Studie (Latin). Forum des Praktischen und Allgemeinarztes. 1986;25:18–22.
Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J. 1988;1(4):351–5.
Hansen NC, Skriver A, Brorsen-Riis L. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med. 1994;88(7):531–5.
Boman G, Backer U, Larsson S, Melander B, Wahlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 1983;64(6):405–15.
Grassi C, Morandini GC. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol. 1976;9(5–6):393–6.
Borgia M, Sepe N, Ori-Belometti M, Borgia R. Confrontotra acetilcisteina e placebo nel trattamento a lungo termine della bronchite cronica (Latin). Gaz Med It. 1981;140:467–72.
Multicenter Study Group. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study. Eur J Respir Dis. 1980;111:93–108.
Parr GD, Huitson A. Oral Fabrol (oral N-acetylcysteine) in chronic bronchitis. Br J Dis Chest. 1987;81(4):341–8.
Schermer T, Chavannes N, Dekhuijzen R, et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med. 2009;103(4):542–51.
Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet. 1965;1(7389):775–9.
Poole P. Methylcysteine hydrochloride in chronic bronchitis. Respir Med COPD Update. 2006;2:64–6.
Cohn LD, Becker BJ. How meta-analysis increases statistical power. Psychol Methods. 2003;8(3):243–53.
Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax. 2009;64(10):894–900.
Manuel M, Esteban M, Concepcion G, Julio C. N-Acetyl-l-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol. 2011;82(5):548–55.
Acknowledgements
We are grateful to the authors of the primary studies included in this meta-analysis and thank Jun-fei Hu for his review and valuable feedback of the manuscript.
Funding
Sponsorship for this study and article processing charges were funded by projects in the Science and Technology Pillar Program from the Department of Science and Technology of Sichuan province (2015SZ0111). All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Authors’ Contribution
Jia Wei and Hao Yan initiated and coordinated the study. Cai-shuang Pang and Juan Han were responsible for the data collection and data analysis. Studies were reviewed by Hao Yan. Jia Wei wrote the first draft of the manuscript. All the authors were involved in the interpretation of the analyses and gave input to the final manuscript.
Disclosures
Jia Wei, Cai-shuang Pang, Juan Han, and Hao Yan have nothing to disclosure.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.
Data Availability
All data generated or analyzed during our study are included in this published article/as supplementary information files.
Author information
Authors and Affiliations
Corresponding author
Additional information
Enhanced Digital Features
To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.9901982.
Rights and permissions
About this article
Cite this article
Wei, J., Pang, Cs., Han, J. et al. Effect of Orally Administered N-Acetylcysteine on Chronic Bronchitis: A Meta-analysis. Adv Ther 36, 3356–3367 (2019). https://doi.org/10.1007/s12325-019-01111-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-019-01111-4